120 related articles for article (PubMed ID: 25889895)
1. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
2. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
3. Identification of RSK substrates using an analog-sensitive kinase approach.
Lizcano-Perret B; Vertommen D; Herinckx G; Calabrese V; Gatto L; Roux PP; Michiels T
J Biol Chem; 2024 Mar; 300(3):105739. PubMed ID: 38342435
[TBL] [Abstract][Full Text] [Related]
4. Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion.
Méant A; Gao B; Lavoie G; Nourreddine S; Jung F; Aubert L; Tcherkezian J; Gingras AC; Roux PP
Mol Cell Proteomics; 2020 Jan; 19(1):50-64. PubMed ID: 31678930
[TBL] [Abstract][Full Text] [Related]
5. Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.
Derewenda U; Artamonov M; Szukalska G; Utepbergenov D; Olekhnovich N; Parikh HI; Kellogg GE; Somlyo AV; Derewenda ZS
Acta Crystallogr D Biol Crystallogr; 2013 Feb; 69(Pt 2):266-75. PubMed ID: 23385462
[TBL] [Abstract][Full Text] [Related]
6. P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?
Koutsougianni F; Alexopoulou D; Uvez A; Lamprianidou A; Sereti E; Tsimplouli C; Ilkay Armutak E; Dimas K
Biochem Pharmacol; 2023 Apr; 210():115488. PubMed ID: 36889445
[TBL] [Abstract][Full Text] [Related]
7. Ribosomal S6 kinase 2-forkhead box protein O4 signaling pathway plays an essential role in melanogenesis.
Jeung D; Lee GE; Chen W; Byun J; Nam SB; Park YM; Lee HS; Kang HC; Lee JY; Kim KD; Hong YS; Lee CJ; Kim DJ; Cho YY
Sci Rep; 2024 Apr; 14(1):9440. PubMed ID: 38658799
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of p90 ribosomal S6 kinase.
Wright EB; Lannigan DA
Front Cell Dev Biol; 2023; 11():1297292. PubMed ID: 38169775
[TBL] [Abstract][Full Text] [Related]
10. Ribosomal S6 Kinase Regulates the Timing and Entrainment of the Mammalian Circadian Clock Located in the Suprachiasmatic Nucleus.
Hoyt KR; Li A; Yoon H; Weisenseel Z; Watkins J; Fischer A; Obrietan K
Neuroscience; 2023 Apr; 516():15-26. PubMed ID: 36796752
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.
M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M
Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625
[TBL] [Abstract][Full Text] [Related]
12. The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity.
Suleiman M; Al Najjar A; Zakaria ZZ; Ahmed R; Yalcin HC; Korashy HM; Uddin S; Riaz S; Abdulrahman N; Mraiche F
J Cardiovasc Transl Res; 2024 Apr; 17(2):334-344. PubMed ID: 37725271
[TBL] [Abstract][Full Text] [Related]
13. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.
Sechi M; Lall RK; Afolabi SO; Singh A; Joshi DC; Chiu SY; Mukhtar H; Syed DN
Sci Rep; 2018 Oct; 8(1):15726. PubMed ID: 30356079
[TBL] [Abstract][Full Text] [Related]
14. Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP.
Hambright HG; Batth IS; Xie J; Ghosh R; Kumar AP
Mol Carcinog; 2015 Oct; 54(10):1227-34. PubMed ID: 25043857
[TBL] [Abstract][Full Text] [Related]
15. YANK2 activated by Fyn promotes glioma tumorigenesis via the mTOR-independent p70S6K activation pathway.
Shi Y; Cheng Y; Wang W; Tang L; Li W; Zhang L; Yuan Z; Zhu F; Duan Q
Sci Rep; 2024 May; 14(1):10507. PubMed ID: 38714727
[TBL] [Abstract][Full Text] [Related]
16. The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling.
Alasady MJ; Terry AR; Pierce AD; Cavalier MC; Blaha CS; Adipietro KA; Wilder PT; Weber DJ; Hay N
PLoS One; 2021; 16(8):e0256238. PubMed ID: 34411141
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascades.
Smolen KA; Papke CM; Swingle MR; Musiyenko A; Li C; Salter EA; Camp AD; Honkanen RE; Kettenbach AN
J Biol Chem; 2023 Sep; 299(9):105154. PubMed ID: 37572851
[TBL] [Abstract][Full Text] [Related]
18. Interactions between sleep disruption, motor learning, and p70 S6 kinase 1 signaling.
Kam K; Kang M; Eren CY; Pettibone WD; Bowling H; Taveras S; Ly A; Chen RK; Berryman NV; Klann E; Varga AW
Sleep; 2020 Mar; 43(3):. PubMed ID: 31608388
[TBL] [Abstract][Full Text] [Related]
19. Developmental regulation of p70 S6 kinase by a G protein-coupled receptor dynamically modelized in primary cells.
Musnier A; Heitzler D; Boulo T; Tesseraud S; Durand G; Lécureuil C; Guillou H; Poupon A; Reiter E; Crépieux P
Cell Mol Life Sci; 2009 Nov; 66(21):3487-503. PubMed ID: 19730801
[TBL] [Abstract][Full Text] [Related]
20. Electrophilic fragment-based design of reversible covalent kinase inhibitors.
Miller RM; Paavilainen VO; Krishnan S; Serafimova IM; Taunton J
J Am Chem Soc; 2013 Apr; 135(14):5298-301. PubMed ID: 23540679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
